Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Trial Profile

Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocortisone (Primary)
  • Indications Adrenal insufficiency; Congenital adrenal hyperplasia
  • Focus Adverse reactions; Registrational
  • Acronyms Infacort004
  • Sponsors Diurnal
  • Most Recent Events

    • 20 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 13 Feb 2018 According to a Diurnal media release, received paediatric use marketing authorisation (PUMA) for Alkindi from the European Commission (EC).
    • 15 Dec 2017 According to a Diurnal media release, the CHMP of the EMA, has issued a positive opinion to the European Commission recommending Alkindi (Infacort hydrocortisone granules in capsules for opening) as replacement therapy for paediatric adrenal insufficiency. The positive opinion from the CHMP is based on review of data from this trial. The final decision on the paediatric use marketing authorisation (PUMA) from the European Commission is anticipated in February 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top